Sandu Pharma Confirms FY26 SEBI Compliance, Past Fine Paid

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Sandu Pharma Confirms FY26 SEBI Compliance, Past Fine Paid
Overview

Sandu Pharmaceuticals has filed its annual compliance report for the fiscal year ending March 2026. The report confirms adherence to SEBI regulations and notes a past INR 30,000 fine for delayed financial results, which has since been paid.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Sandu Pharmaceuticals Files FY26 Compliance Report

Sandu Pharmaceuticals Ltd. has submitted its Annual Secretarial Compliance Report for the fiscal year ended March 31, 2026. The filing confirms the company's adherence to regulatory requirements and clarifies a past compliance matter.

Report Highlights

Prepared by Practising Company Secretary CS Swapnil J Dixit, the report confirms Sandu Pharmaceuticals' overall compliance with key SEBI regulations. This includes adherence to listing obligations, website disclosures, internal policies, insider trading norms, and record maintenance.

Governance Assurance and Past Fine

The report provides shareholders and stakeholders with assurance regarding the company's commitment to regulatory frameworks and strong corporate governance.

Notably, the filing acknowledges a past fine of INR 30,000 plus 18% GST. This penalty was levied due to a delay in submitting financial results under Regulation 33. The company has confirmed that this fine has been fully paid, resolving the matter.

Company Background and Industry Context

Sandu Pharmaceuticals is an Indian company focused on manufacturing and marketing Ayurvedic medicines. It operates within the strictly regulated pharmaceutical sector. Competitors in the Ayurvedic and herbal medicine space, such as Dabur India and Emami Ltd., also navigate complex regulatory landscapes for their operations and filings.

What This Means for Investors

This submission is a routine governance check that reinforces ongoing regulatory adherence. The resolution of the past penalty means there are no new or ongoing material risks highlighted by this specific filing concerning operations or compliance. No immediate changes to shareholding structure or investor rights are implied.

Future Tracking

Investors will likely monitor future Annual Secretarial Compliance Reports from Sandu Pharmaceuticals, along with general business performance updates, new product launches, and any further regulatory announcements from SEBI or the stock exchanges.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.